Soleno Therapeutics (NASDAQ: SLNO): Earnings, Legal Challenges, and Financial Health Insights

Font: Financial Modeling Prep  • May 05, 2026

• Upcoming Soleno Therapeutics (NASDAQ: SLNO) earnings report on May 6, 2026, with an EPS estimate of $0.73 and revenue forecast of $93.78 million.
• The biopharmaceutical company is currently facing a securities class action lawsuit, impacting investors who purchased common stock between March 26, 2025, and November 4, 2025.
• Soleno Therapeutics exhibits a high P/E ratio of 134.71, alongside strong financial stability indicated by a low debt-to-equity ratio of 0.006 and a healthy current ratio of 5.80.

Soleno Therapeutics (NASDAQ: SLNO) is a biopharmaceutical company. It focuses on developing and commercializing new treatments for rare diseases. The company operates in a specialized part of the healthcare industry where success often depends on positive clinical trial data and gaining approval from regulatory bodies for its potential products.

On May 6, 2026, Soleno Therapeutics is scheduled to release its quarterly earnings report before the market opens. Wall Street analysts have an earnings per share (EPS) estimate of $0.73. EPS is a measure of a company's profit allocated to each outstanding share of stock. The revenue is forecasted to be approximately $93.78 million for the quarter.

At the same time, the company is facing legal issues. As highlighted by PR Newswire, the law firm Hagens Berman is reminding investors about a securities class action lawsuit. The lawsuit is for investors who bought Soleno Therapeutics common stock between March 26, 2025, and November 4, 2025, and experienced significant losses.

Looking at its financial metrics, Soleno Therapeutics has a trailing twelve-month price-to-earnings (P/E) ratio of 134.71. A high P/E ratio can suggest that investors expect higher earnings growth in the future compared to the overall market. The company's price-to-sales ratio is 14.49, while its enterprise value-to-sales ratio is 14.13.

The company's balance sheet shows a low debt-to-equity ratio of 0.006, which means it uses very little debt to finance its assets. Soleno Therapeutics also has a healthy current ratio of 5.80. This ratio indicates that the company has enough short-term assets to cover its short-term liabilities, suggesting good financial stability.